Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 23;20(10):e0334434.
doi: 10.1371/journal.pone.0334434. eCollection 2025.

Myasthenia gravis and autoimmune overlap: Prognostic insight

Emel Oguz-Akarsu  1 , Sarra El Hamida Lazrak  1 , Deniz Sigirli  2   3 , Gizem Gullu  1 , Yasemin Dinç  1 , Furkan Saridas  1 , Necdet Karli  1
Affiliations

Myasthenia gravis and autoimmune overlap: Prognostic insight

Emel Oguz-Akarsu et al. PLoS One. .

Abstract

Background: Autoimmune diseases (ADs) frequently coexist with myasthenia gravis (MG), suggesting shared genetic and immunological mechanisms. However, the impact of comorbid ADs on MG prognosis remains unclear. This study aimed to investigate the prevalence, clinical characteristics, and prognosis of MG patients with comorbid ADs in a Turkish cohort.

Methods: We retrospectively analyzed 302 MG patients treated at a tertiary center between 2010 and 2024. Patients were grouped based on the presence of comorbid ADs. Clinical characteristics, disease severity, treatment response, and prognosis were compared.

Results: Among 302 MG patients, 41 (13.6%) had at least one comorbid AD, with autoimmune thyroid disease (AITD) being the most common (10.6%). ADs were more frequent in females. Patients with and without comorbid ADs showed no significant differences in MG severity, thymectomy rates, myasthenic exacerbations, or overall outcomes (p > 0.05). However, female patients with ADs experienced more frequent myasthenic exacerbations and had a higher rate of rituximab use (p < 0.05).

Conclusions: Comorbid ADs do not significantly impact MG severity or prognosis. Female MG patients with ADs have a higher frequency of myasthenic exacerbations and rituximab use, warranting further research. Early identification of ADs remains essential for optimal patient management.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

References

    1. Anaya J-M, Gómez L, Castiblanco J. Is there a common genetic basis for autoimmune diseases?. Clin Dev Immunol. 2006;13(2–4):185–95. doi: 10.1080/17402520600876762 - DOI - PMC - PubMed
    1. Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev. 2003;2(3):119–25. doi: 10.1016/s1568-9972(03)00006-5 - DOI - PubMed
    1. Nacu A, Andersen JB, Lisnic V, Owe JF, Gilhus NE. Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity. 2015;48(6):362–8. doi: 10.3109/08916934.2015.1030614 - DOI - PMC - PubMed
    1. Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235. doi: 10.3390/jcm10112235 - DOI - PMC - PubMed
    1. Zhong H, Zhao C, Luo S. HLA in myasthenia gravis: from superficial correlation to underlying mechanism. Autoimmun Rev. 2019;18(9):102349. doi: 10.1016/j.autrev.2019.102349 - DOI - PubMed